69.77.050 – Informed consent.
RCW 69.77.050 Informed consent. (1) Prior to treatment of the eligible patient with an investigational product, the treating physician shall obtain written informed consent, consistent with the requirements of RCW 7.70.060(1), and signed by the eligible patient or, if the patient lacks the capacity to consent, his or her legally authorized representative. (2) Information provided […]
69.77.060 – Issuer may provide coverage for cost or administration of investigational product—Denial of coverage.
RCW 69.77.060 Issuer may provide coverage for cost or administration of investigational product—Denial of coverage. (1) An issuer may, but is not required to, provide coverage for the cost or the administration of an investigational product provided to an eligible patient pursuant to this chapter. (2)(a) An issuer may deny coverage to an eligible patient […]
69.77.070 – Hospitals and health care facilities.
RCW 69.77.070 Hospitals and health care facilities. A hospital or health care facility: (1) May, but is not required to, allow a health care practitioner who is privileged to practice or who is employed at the hospital or health care facility to treat, administer, or provide an investigational product to an eligible patient under this […]
69.77.080 – Private right of action—Unprofessional conduct—Immunity from civil or criminal liability.
RCW 69.77.080 Private right of action—Unprofessional conduct—Immunity from civil or criminal liability. (1) Chapter 212, Laws of 2017 does not create a private right of action. (2) A health care practitioner does not commit unprofessional conduct under RCW 18.130.180 and does not violate the applicable standard of care by: (a) Obtaining an investigational product pursuant […]
69.77.090 – Pharmacy quality assurance commission may adopt rules.
RCW 69.77.090 Pharmacy quality assurance commission may adopt rules. The pharmacy quality assurance commission may adopt rules necessary to implement this chapter. [ 2017 c 212 § 9.]
69.80.010 – Purpose.
RCW 69.80.010 Purpose. The purpose of this chapter is to promote the free distribution of food to needy persons, prevent waste of food products, and provide liability protection for persons and organizations donating or distributing such food products. [ 1983 c 241 § 1.]
69.80.020 – Definitions.
RCW 69.80.020 Definitions. Unless the context clearly requires otherwise, the definitions in this section apply throughout this chapter. (1) “Distributing organization” means a charitable nonprofit organization under section 501(c) of the federal internal revenue code which distributes food free of charge and includes any nonprofit organization that distributes food free of charge to other nonprofit […]
69.75.020 – Retail sales—Proof of age from purchaser—Unlawful acts, exceptions—Penalties.
RCW 69.75.020 Retail sales—Proof of age from purchaser—Unlawful acts, exceptions—Penalties. (1) A person making a retail sale of a finished drug product containing any quantity of dextromethorphan must require and obtain proof of age from the purchaser before completing the sale, unless from the purchaser’s outward appearance the person making the sale would reasonably presume […]
69.75.030 – List of products containing dextromethorphan, trade association representing manufacturers to supply.
RCW 69.75.030 List of products containing dextromethorphan, trade association representing manufacturers to supply. The trade association representing manufacturers of dextromethorphan shall supply to the pharmacy quality assurance commission and requesting licensed retailers an initial list of products containing dextromethorphan that its members market. This list shall be updated on an annual basis. The trade association […]
69.75.040 – Construction of chapter.
RCW 69.75.040 Construction of chapter. (1) Nothing in this chapter is construed to impose any compliance requirement on a retail entity other than manually obtaining and verifying proof of age as a condition of sale, including placement of products in a specific place within a store, other restrictions on consumers’ direct access to finished drug […]